

26<sup>th</sup> April 2024

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001  <b>Scrip Code: BSE – AJANTPHARM 532331</b>	National Stock Exchange of India, Exchange Plaza, 5 <sup>th</sup> Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051  <b>Scrip Code: NSE AJANTPHARM EQ</b>
--	--

**Sub.: Prior Intimation of Board Meeting of Ajanta Pharma Limited (“the Company”) to consider the Buy-back offer**

**Ref.: Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“Listing Regulations”)**

Dear Sirs/Madam,

Pursuant to Regulation 29(1)(b) of the Listing Regulations and in continuation to our intimation dated April 22, 2024 about meeting of the Board of Directors of the Company scheduled to be held on Thursday, May 2, 2024, we hereby inform that at the said meeting, the Board will also consider a proposal for buy-back of Equity Shares of the Company and other matters incidental and necessary thereto, in accordance with the applicable provisions of the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws.

Kindly take this on your record & disseminate.

Thanking you,

Yours faithfully,

**Gaurang Shah**

*VP – Legal & Company Secretary*